IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i6d10.1007_s41669-024-00520-8.html
   My bibliography  Save this article

Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK

Author

Listed:
  • Danny Gibson

    (AstraZeneca, Health Economics)

  • Neil Branscombe

    (AstraZeneca, Health Economics)

  • Neil Martin

    (AstraZeneca, Health Economics
    University of Leicester)

  • Andrew Menzies-Gow

    (AstraZeneca, Health Economics)

  • Priya Jain

    (AstraZeneca, Health Economics)

  • Katherine Padgett

    (Health Economics and Outcomes Research Ltd)

  • Florian Yeates

    (Health Economics and Outcomes Research Ltd)

Abstract

Background Oral corticosteroids (OCS) are effective anti-inflammatory agents used across a range of conditions. However, substantial evidence associates their use with increased risks for adverse events (AEs), causing high burden on healthcare resources. Emerging biologics present as alternative agents, enabling the reduction of OCS use. However, current modelling approaches may underestimate their effects by not capturing OCS-sparing effects. In this study, we present a modelling approach designed to capture the health economic benefits of OCS-sparing regimens and agents. Methods We developed a disease-agnostic model using a UK health technology assessment (HTA) perspective, with discounting of 3.5% for costs and outcomes, a lifetime horizon, and 4-week cycle length. The model structure included type 2 diabetes mellitus, established cardiovascular disease, and osteoporosis as key AEs and drivers of morbidity and mortality, as well as capturing transient events. Quality-adjusted life-years (QALYs), life-years, and costs were determined for OCS-only and OCS-sparing treatment arms. Outcomes were determined using baseline 50% OCS-sparing, considering several OCS average daily doses (5, 10, 15 mg). Results A treatment regimen with 50% OCS dose-sparing led to lifetime incremental cost savings per patient of £1107 (95% confidence interval £1014–£1229) at 5 mg, £2403 (£2203–£2668) at 10 mg, and £19,501 (£748–£51,836) at 15 mg. Patients also gained 0.033 (0.030–0.036) to 0.356 (0.022–2.404) QALYs dependent on dose. The benefits of OCS sparing were long-term, plateauing after 35–40 years of treatment. Conclusions We present a modelling approach that captures additional long-term health economic benefits from OCS sparing that would otherwise be missed from current modelling approaches. These results may help inform future decision making for emerging OCS-sparing therapeutics by comparing them against the cost of such treatments.

Suggested Citation

  • Danny Gibson & Neil Branscombe & Neil Martin & Andrew Menzies-Gow & Priya Jain & Katherine Padgett & Florian Yeates, 2024. "Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK," PharmacoEconomics - Open, Springer, vol. 8(6), pages 923-934, November.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00520-8
    DOI: 10.1007/s41669-024-00520-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00520-8
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-024-00520-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00520-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.